Article info
PDFNeurological rarities
Guanidinoacetate methyltransferase (GAMT) deficiency: a rare but treatable epilepsy
- Correspondence to Dr William M Stern, Clinical and Experimental Epilepsy, Institute of Neurology, 33 Queen Square, London WC1N 3BG, UK; williamstern{at}doctors.org.uk
Citation
Guanidinoacetate methyltransferase (GAMT) deficiency: a rare but treatable epilepsy
Publication history
- Received July 12, 2016
- Revised November 20, 2016
- Accepted November 25, 2016
- First published January 24, 2017.
Online issue publication
July 05, 2017
Article Versions
- Previous version (26 May 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- P19 Clinical pearl: pharmaceutical management of siblings with guanidinoacetate methyltransferase (gamt) deficiency
- Phenotype and genotype in 101 males with X-linked creatine transporter deficiency
- GP223 Creatine deficiency disorders the all-ireland experience
- Neurodegenerative disorders and metabolic disease
- Investigating adults with early-onset epilepsy and intellectual or physical disability
- POE05 A low creatinine in developmental delay, epilepsy and movement disorders—does it matter?
- Creatine transporter deficiency, an underdiagnosed cause of male intellectual disability
- 4CPS-188 Galenic preparations and rare diseases: guanidinoacetate methyltransferase deficiency: experience in a local hospital
- PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease
- Highlights from this issue